Clicky

Ultragenyx Pharmaceutical Inc.(RARE) News

Date Title
Apr 12 Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Mar 20 10 NASDAQ Stocks with Biggest Upside
Mar 12 Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
Mar 11 Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
Mar 8 10 Biotech Stocks with Huge Potential
Jan 25 Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Jan 9 After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
Jan 7 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
Jan 4 Ultragenyx (RARE) Posts Update From AS Study of GTX-102
Jan 4 Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Jan 3 Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
Jan 2 Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 27 13 Most Promising Future Stocks To Buy According To Hedge Funds
Dec 21 Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
Dec 21 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 18 Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Sep 7 Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ...
Aug 11 Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies
Aug 10 Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line
Aug 8 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate